[Ip-health] Reminder - Discussion of today's Supreme Court oral arguments in FTC v. Actavis (reverse payment case)

Michael Palmedo mpalmedo at wcl.american.edu
Mon Mar 25 10:23:03 PDT 2013


Mar 25, 2013 | 4:00 - 5:30 | Room 602

American University Washington College of Law 

 

Open to the public and webcast live and on demand at
http://www.pijip-impact.org/events/ftc-v-watson/

 

In PIJIP's ongoing Supreme Court series, counsel for parties and amici
will discuss intellectual property cases on the afternoon of oral
argument, addressing the reaction of the Court at oral argument.  In
this case the Supreme Court examines whether reverse-payment agreements
are per se lawful unless the underlying patent litigation was a sham or
the patent was obtained by fraud (as the court below held), or instead
are presumptively anticompetitive and unlawful (as the Third Circuit has
held).  Reverse payment agreements are a type of settlement agreement
where brand-name drug manufacturers pay potential generic competitors to
agree not to sell competing generic drugs for a period of years.

 

-          Michael Carroll - Washington College of Law, Moderator

-          Julia York - Skadden, Arps, Slate, Meagher & Flom LLP,
counsel for Respondent, Actavis, Inc.

-          Rohit Singla- Munger, Tolles & Olson LLP, counsel for
Respondent, Solvay Pharmaceuticals, Inc.

-          Ryan Christian - White & Case LLP, counsel for Respondent,
Par Pharmaceutical Companies, Inc.

-          Julia York - Skadden, Arps, Slate, Meagher & Flom LLP,
counsel for Respondent, Actavis, Inc.

-          Krista Cox - Knowledge Ecology International, counsel for
amicus Knowledge Ecology International, supporting Petitioner

-          Scott Hemphill - Columbia Law School

 

 

 

 

--

Mike Palmedo

Program on Information Justice and Intellectual Property

American University Washington College of Law

4801 Massachusetts Ave., NW, Washington, D.C. 20016

W: 202-274-4442 | M: 571-289-3683

wcl.ameican.edu | infojustice.org | pijip-impact.org

 




More information about the Ip-health mailing list